Physician profile
Yueming Chang
NPI 1629398904
$586.54
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $29.45 · 2021: $149 · 2022: $79.93.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $247.03 | 2019-2020 | |
| Incyte Corporation | $137.32 | 2021 | |
| Lilly USA, LLC | $72.84 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $36.63 | 2019-2022 | |
| Glaxosmithkline, LLC. | $32.19 | 2022 | |
| Amgen INC. | $18.93 | 2022 | |
| Janssen Biotech, INC. | $15.66 | 2019 | |
| Jazz Pharmaceuticals INC. | $14.02 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yueming Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.